Geltor’s tailored protein biodesign platform

By William Smith
Geltor is a San Leandro, California-based “biodesign” company, making animal-free proteins for consumer products...

Geltor is a San Leandro, California-based “biodesign” company, making animal-free proteins for consumer products.

Examples are the collagen and elastin found in beauty, food and beverage products, with more ethically-minded consumers increasingly clamouring for more sustainable solutions and companies keen to market their efforts to move away from animal ingredients.

Geltor describes its offering as an ingredients-as-a-service platform, which uses fermentation technology to produce required ingredients for customers.

Geltor said global demand for collagen has risen by 25% in the past year, and that is has duly scaled its platform up by 100 times.

Since its foundation in 2015, the startup has raised over $114mn across six funding rounds. Its latest Series B round, announced earlier this week, saw the company raise $93.1mn from lead investor CPT Capital, alongside iSELECT FUND, WTT Investment, SOSV, RIT Capital Partners, Pegasus Tech Ventures, Humboldt Fund, Gelita AG, Cultivian Sandbox Ventures, CPT Capital and Blue Horizon Ventures.

In a press release, Geltor CEO and co-founder Alex Lorestani said: "Our goal is to make it ridiculously easy for iconic brands to build sustainable products. This next stage of growth will allow Geltor to meet the moment our world is facing, as businesses recognize the urgent need to transition to a sustainable protein supply chain.

“We're grateful to have investors who see Geltor as an index of this important shift to a system powered by fermentation and plant-based platforms like ours. As a scientist, I'm convinced that the highest-impact action I can take to support human and planetary health is making our Ingredients-as-a-Service™ platform better every single day."

The company said it would use the funds to meet what it described as accelerating demand for its ingredients from consumer packaged goods firms.

"Having established the success of our biodesign platform, we are now able to work even more closely with customers to develop unique tailored bioactive ingredients for their specific product needs. We've only scratched the surface of what our technology can unlock for our clients at unprecedented speed," said Chief Technology Officer and co-founder Nick Ouzounov.

(Image: Geltor)


Featured Articles

HPV Vaccine 'Protects Males from Cancers' - Global Report

As a new report shows the human papillomavirus vaccine can also protect men and boys, we take a look at HPV vaccines, and their impact on world health

Tata Consultancy Report Shows AI in Healthcare on Rise

Tata Consultancy Services AI for Business Global Study shows that three-quarters of healthcare leaders are deploying AI to drive innovation and efficiency

McKinsey: Consumers Demand Data-driven Wellness Products

New McKinsey Future of Wellness survey shows that consumers demand data-driven wellness solutions to improve health, sleep, nutrition, fitness & longevity

SpaceX Starlink Launch Boost for Indonesia Healthcare

Technology & AI

J&J Targets Supplier Sustainability to Cut Healthcare GHGs


Walgreens to Sell Over-the-Counter Opioid Overdose Drug

Medical Devices & Pharma